Liver Transplant with MCC or Intestinal Transplant DRG Reimbursement

Perioperative immunosuppression optimization trials: randomized or adaptive studies testing different immunosuppressive regimens, dosing strategies, or timing around liver transplant (including combined liver–intestinal transplants) to reduce early graft rejection and infection. These trials enroll adult and pediatric transplant recipients during the index hospitalization or immediately post‑op, comparing standard multi‑drug protocols versus modified induction or maintenance approaches with close monitoring of rejection episodes and infectious complications. Results are relevant to providers for tailoring in‑hospital management and to payers because optimized regimens can reduce ICU stays, reoperations, readmissions, and high‑cost complications that drive DRG costs.
Organ preservation and donor management studies: prospective trials evaluating novel organ preservation techniques, machine perfusion parameters, or donor optimization protocols to improve graft viability for marginal livers and intestinal grafts. These studies typically involve deceased‑donor organs and recipients listed for high‑risk transplant, assessing outcomes such as primary graft nonfunction, ischemia‑reperfusion injury, and need for re‑transplantation within 30–90 days. For hospitals and payers, better preservation can increase usable organ yield, lower perioperative morbidity, shorten lengths of stay, and reduce expensive salvage therapies under this DRG.
Post‑discharge outcomes and care‑coordination studies: cohort or pragmatic trials of structured transitional care, surveillance protocols, and outpatient multidisciplinary management to prevent late complications such as chronic rejection, biliary or anastomotic complications, and hospital readmissions. These studies follow liver and intestinal transplant recipients after the index DRG episode, often targeting high‑risk subgroups (e.g., patients with multi‑organ failure pre‑transplant or those with socioeconomic barriers), and measure readmission rates, long‑term graft survival, quality of life, and cumulative cost of care. Findings inform providers on effective post‑acute pathways and help payers identify interventions that reduce downstream utilization and total cost associated with this DRG.

Perioperative immunosuppression optimization trials: randomized or adaptive studies testing different immunosuppressive regimens, dosing strategies, or timing around liver transplant (including combined liver–intestinal transplants) to reduce early graft rejection and infection. These trials enroll adult and pediatric transplant recipients during the index hospitalization or immediately post‑op, comparing standard multi‑drug protocols versus modified induction or maintenance approaches with close monitoring of rejection episodes and infectious complications. Results are relevant to providers for tailoring in‑hospital management and to payers because optimized regimens can reduce ICU stays, reoperations, readmissions, and high‑cost complications that drive DRG costs.
Organ preservation and donor management studies: prospective trials evaluating novel organ preservation techniques, machine perfusion parameters, or donor optimization protocols to improve graft viability for marginal livers and intestinal grafts. These studies typically involve deceased‑donor organs and recipients listed for high‑risk transplant, assessing outcomes such as primary graft nonfunction, ischemia‑reperfusion injury, and need for re‑transplantation within 30–90 days. For hospitals and payers, better preservation can increase usable organ yield, lower perioperative morbidity, shorten lengths of stay, and reduce expensive salvage therapies under this DRG.
Post‑discharge outcomes and care‑coordination studies: cohort or pragmatic trials of structured transitional care, surveillance protocols, and outpatient multidisciplinary management to prevent late complications such as chronic rejection, biliary or anastomotic complications, and hospital readmissions. These studies follow liver and intestinal transplant recipients after the index DRG episode, often targeting high‑risk subgroups (e.g., patients with multi‑organ failure pre‑transplant or those with socioeconomic barriers), and measure readmission rates, long‑term graft survival, quality of life, and cumulative cost of care. Findings inform providers on effective post‑acute pathways and help payers identify interventions that reduce downstream utilization and total cost associated with this DRG.

OpenPayer

Summary & Overview

Liver Transplant with MCC or Intestinal Transplant: Inpatient Reimbursement Overview

DRG 005 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes